Efgartigimod IV

Phase 3

argenx SE (ARGX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

ARGXPhase 3$58.8B

Efgartigimod IV Phase 3 Est. Readout

Efgartigimod IV• Generalized Myasthenia Gravis12

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Generalized Myasthenia Gravis

View Full Landscape

Drug Information

Target Indication

Generalized Myasthenia Gravis

Clinical Trial

NCT04833894

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

Efgartigimod PH20 SCPhase 3

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EFG PH20 SCPhase 3

Active Idiopathic Inflammatory Myopathy

IVIG (Intravenous Immunoglobulin)Phase 3

Multifocal Motor Neuropathy (MMN)

EfgartigimodPhase 3

Postural Orthostatic Tachycardia Syndrome

ARGX-113Phase 3

Pemphigus Vulgaris

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts